Any Second-Line Therapy for Advanced Pancreatic Cancer? Highlights from the '2010 ASCO Gastrointestinal Cancers Symposium'. Orlando, FL, USA. January 22-24, 2010
Abstract
Majority of pancreatic cancers are unresectable upon diagnosis. Palliative chemotherapy is usually administered in an attempt of prolonging survival potentially and providing quality of life. Gemcitabine has been the solo player in the field of pancreatic cancer treatment after replacing 5-FU since 1997. How to treat a patient with advanced pancreatic cancer failing to respond or progressing after gemcitabine is a true challenge. No established second-line treatment exists yet. Chinese herbal medicine PHY906 provides cytoprotective effects without dampening the anti-tumor activity of chemotherapeutic agents. Several combinations such as S-1/gemcitabine, GTX, FOLFIRINOX showed promising results in retrospective studies. Among single agents, erlotinib and Src inhibitor failed to show seemingly benefit, while abraxane and pemetrexed deserve further investigation.
Image: Yale Cancer Center. New Haven, CT, USA.
Downloads
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385] (FULL TEXT: http://caonline.amcancersoc.org/cgi/content/full/59/4/225)
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [PMID 9196156] (FULL TEXT: http://jco.ascopubs.org/cgi/reprint/15/6/2403.pdf)
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6. [PMID 17452677] (FULL TEXT: http://jco.ascopubs.org/cgi/content/full/25/15/1960)
Saif M, Li J, Chu E, Lamb L, Kaley K, Elligers K, et al. Phase II study of PHY906 plus capecitabine (CAP) in patients with gemcitabine-refractory advanced pancreatic cancer (APC). 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 246. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1695)
Nakamori S, Tsujie M, Miyamoto A, Kurokawa Y, Yasui M, Ikenaga M, et al. Impact of the combination of S-1 administration prior to gemcitabine as a second-line therapy for unresectable/recurrent pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 241. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1627)
Breysacher G, Kaatz O, Lemarignier C, Chiappa P, Roncalez D, Denis B; et al. Safety and clinical effectiveness of FOLFIRINOX in metastatic pancreas cancer (MPC) after first-line chemotherapy. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 269. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1999)
Dakik HK, Moskovic DJ, Carlson PJ, Qiao W, Ho L, Tamm E, et al. Evaluation of gemcitabine, docetaxel, capecitabine (GTX) in previously treated pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 221. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1602)
Nallapareddy S, Arcaroli J, Touban B, Tan A, Foster NR, Erlichman C, et al. A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 165. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1452)
Hosein PJ, Pastorini VH, Gomez CM, Macintyre J, Merchan JR, Ferrell A, et al. A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine-based therapy. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 214. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2091)
Iyer RV, Khushalani NI, Tan W, Litwin A, Starostik P, Levea C, et al. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G). 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 258. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2159)
Bai W, He AR, Pishvaian MJ, Slack R, Marshall J, Ley L, et al. Pemetrexed as second-line treatment in patients with advanced pancreatic cancer progressing after gemcitabine. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 276. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2041)
Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 2009; 27(15 Suppl):Abstract 4525. (FULL TEXT: http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4525)
Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S, et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 2009; 15:4138-46. [PMID 19509160] (FULL TEXT: http://clincancerres.aacrjournals.org/content/15/12/4138.long)
Copyright (c) 2010 Jia Li, Man Yee Merl, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.